PMID- 38311835
OWN - NLM
STAT- Publisher
LR  - 20240205
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
DP  - 2024 Feb 4
TI  - Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A 
      Systematic Review and Meta-Analysis.
LID - 10.1002/jcph.2402 [doi]
AB  - Hepatocellular carcinoma (HCC) is often diagnosed in advanced stages. Following 
      sorafenib, lenvatinib (LENV) has been approved as a first-line treatment option 
      for unresectable HCC. In the past few years, at least 9 large-scale cohort 
      studies have examined the efficacy and safety of LENV compared to atezolizumab 
      plus bevacizumab (ATE/BEV) in unresectable HCC, but there is currently no direct 
      meta-analysis conducted for a comprehensive consolidation. To provide the most 
      updated meta-analysis of the clinical efficacy and safety of ATE/BEV versus LENV 
      for patients with unresectable HCC. Our studies comparing the efficacy and safety 
      of ATE/BEV and LENV in unresectable HCC were systematically searched in PubMed, 
      Embase, and Web of Science from inception to February 2023. Outcomes measured 
      were overall survival (OS), progression-free survival (PFS), mortality, complete 
      response (CR), partial response (PR), objective response rate (ORR), disease 
      control rate (DCR), progressive disease (PD), stable disease (SD), and adverse 
      events (AEs). Seven eligible studies involving 4428 patients (1569 in the ATE/BEV 
      group and 2859 in the LENV group) were included in the narrative synthesis. All 
      baseline characteristics were similar between the 2 groups except for Child-Pugh 
      class B. Ultimately, our meta-analysis showed that the LENV group had longer OS 
      and PFS than the ATE/BEV group. Moreover, patients on LENV were more likely to 
      achieve SD, whereas those on ATE/BEV were more likely to achieve PR.
CI  - (c) 2024, The American College of Clinical Pharmacology.
FAU - Lu, Jinpeng
AU  - Lu J
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian 
      Medical University, Fuzhou, Fujian, China.
FAU - Lin, Xinyi
AU  - Lin X
AUID- ORCID: 0009-0008-4084-5020
AD  - Department of Anesthesiology, The First Affiliated Hospital of Fujian Medical 
      University, Fuzhou, Fujian, China.
FAU - Teng, Haiwen
AU  - Teng H
AUID- ORCID: 0009-0005-8721-7273
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian 
      Medical University, Fuzhou, Fujian, China.
FAU - Zheng, Yansong
AU  - Zheng Y
AUID- ORCID: 0000-0001-9621-5134
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Fujian 
      Medical University, Fuzhou, Fujian, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240204
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
SB  - IM
OTO - NOTNLM
OT  - atezolizumab plus bevacizumab
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - treatment
EDAT- 2024/02/05 06:43
MHDA- 2024/02/05 06:43
CRDT- 2024/02/05 00:43
PHST- 2023/10/12 00:00 [received]
PHST- 2023/12/31 00:00 [accepted]
PHST- 2024/02/05 06:43 [medline]
PHST- 2024/02/05 06:43 [pubmed]
PHST- 2024/02/05 00:43 [entrez]
AID - 10.1002/jcph.2402 [doi]
PST - aheadofprint
SO  - J Clin Pharmacol. 2024 Feb 4. doi: 10.1002/jcph.2402.